Marine Cytotoxin Santacruzamate A Derivatives as Potent HDAC1-3 Inhibitors and Their Synergistic Anti-Leukemia Effects with Venetoclax
Marine Drugs · 2024
DOI: 10.3390/md22060250 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2024. Verfasst von Wanting Hao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China. Hauptthemen laut MEDLINE: Sulfonamides, Leukemia, Myeloid, Acute, Histone Deacetylase Inhibitors, Drug Synergism. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, the Taishan Scholars Program.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is a hematologic malignancy characterized by infiltration of the blood and bone marrow, exhibiting a low remission rate and high recurrence rate. Current research has demonstrated that class I HDAC inhibitors can downregulate anti-apoptotic proteins, leading to apoptosis of AML cells. In the present investigation, we conducted structural modifications of marine cytotoxin Santacruzamate A (SCA), a compound known for its inhibitory activity towards HDACs, resulting in the development of a novel series of potent class I HDACs hydrazide inhibitors. Representative hydrazide-based compound 25c exhibited concentration-dependent induction of apoptosis in AML cells as a single agent. Moreover, 25c exhibited a synergistic anti-AML effect when combined with Venetoclax, a clinical Bcl-2 inhibitor employed in AML therapy. This combination resulted in a more pronounced downregulation of anti-apoptotic proteins Mcl-1 and Bcl-xL, along with a significant upregulation of the pro-apoptotic protein cleaved-caspase3 and the DNA double-strand break biomarker γ-H2AX compared to monotherapy. These results highlighted the potential of 25c as a promising lead compound for AML treatment, particularly when used in combination with Venetoclax.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
ORCID-Profile: Yuqi Jiang, Chong Qin, Xiaoyang Li
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- the Taishan Scholars Program
- the Science Foundation for Excellent Young Scholars of Shandong Province
- Science and Technology Support Plan for Youth Innovation in Universities of Shandong Province
- Taishan Scholars Program
- Fundamental Research Funds for the Central Universities-Ocean University of China
- Science Foundation for Excellent Young Scholars of Shandong Province
Zitieren
APA
Hao, W., Wang, L., Xu, T., Jia, G., Jiang, Y., Qin, C., & Li, X. (2024). Marine Cytotoxin Santacruzamate A Derivatives as Potent HDAC1-3 Inhibitors and Their Synergistic Anti-Leukemia Effects with Venetoclax. Marine Drugs. https://doi.org/10.3390/md22060250
Vancouver
Hao W, Wang L, Xu T, Jia G, Jiang Y, Qin C, et al. Marine Cytotoxin Santacruzamate A Derivatives as Potent HDAC1-3 Inhibitors and Their Synergistic Anti-Leukemia Effects with Venetoclax. Marine Drugs. 2024. doi:10.3390/md22060250
BibTeX
@article{Hao2024,
author = {Hao, Wanting and Wang, Leyan and Xu, Tongqiang and Jia, Geng and Jiang, Yuqi and Qin, Chong and Li, Xiaoyang},
title = {Marine Cytotoxin Santacruzamate A Derivatives as Potent HDAC1-3 Inhibitors and Their Synergistic Anti-Leukemia Effects with Venetoclax},
journal = {Marine Drugs},
year = {2024},
doi = {10.3390/md22060250}
}
EUVIMED